Dr. Jordan answers the question: 'How can I be estrogen receptor-positive?' — -- Question: How can my breast cancer be estrogen receptor-positive when I am postmenopausal and my body is losing ...

In this segment, Dr. Gregory Vidal explains why it is essential for patients to understand their hormone receptor status and HER2 status when diagnosed with ER-positive, HER2-negative metastatic ...

A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common ...

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in ...

CLEVELAND, Ohio — A shift toward personalized treatment for breast cancer, ways to help patients live longer without their cancer worsening and a shorter but equally effective treatment for a ...

Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery This open-label, parallel-group trial randomly assigned 132 participants to receive camizestrant 75, 150, or 300 ...

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...